AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 236 min read$DGX

QUEST DIAGNOSTICS INC (DGX): Results of Operations and Financial Condition

QUEST DIAGNOSTICS INC (DGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dgx063020268-kex991.htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 • Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth •

Original reporting
SEC EDGAR 8-K
Published Jul 23, 2026, 10:46 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$DGX
Bullish
high confidence
Mentioned
$DGX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DGXBullishHigh
01

Why it matters

The key tradable update is the raised FY2026 guidance ranges for net revenues and both reported and adjusted diluted EPS, supported by double-digit organic growth and higher Q2 EPS.

02

Market read

Raised FY2026 revenue and EPS guidance provides a concrete catalyst for re-pricing DGX expectations ahead of and during the earnings call.

03

What to watch

The filing highlights tax-contingency resolution affecting the adjusted effective tax rate; traders may discount EPS quality if underlying operating drivers weaken in later quarters.

Relevance 7/10Novelty 9/10Timing: today’s 8:30 a.m. ET conference call after the 8-K guidance raise

Background

This is an SEC Form 8-K with Exhibit 99.1 covering Quest Diagnostics’ Q2 2026 results and updated full-year 2026 guidance.

Company-level read

Ticker impact

$DGXBullishHigh confidence
Context

Quest Diagnostics reported Q2 2026 results and raised full-year 2026 guidance, including net revenue and EPS ranges.

Expected impact

Moderately positive bias for the next session and into the earnings-call window, with follow-through dependent on market expectations versus the raised ranges.

Evidence & confidence

The filing includes specific updated guidance ranges for net revenues, GAAP diluted EPS, and adjusted diluted EPS, plus Q2 outperformance metrics (10%+ revenue growth, 15%+ GAAP EPS growth).

Market effects

Sector

Positive read-through for US diagnostic testing and lab services demand, especially around oncology and specialty testing adoption.

Regional

Primarily US healthcare services sentiment; limited direct regional spillover beyond healthcare equities.

Global

Low direct global impact, but could modestly influence broader healthcare diagnostics risk appetite.

Counterpoint

What could challenge this read

Guidance raises may already be partially priced in ahead of the call; investors may focus on sustainability of organic growth and any margin pressure not captured by adjusted EPS.

Key entities

  • company
    Quest Diagnostics Incorporated

    Subject of the 8-K, reporting Q2 2026 results and raising FY2026 guidance.

  • executive
    Jim Davis

    Chairman, CEO and President quoted on strategy execution and demand.

Read at source← All news

Related articles

JUL 27
$DGXMedAI 8/10

Why Quest Diagnostics Stock Climbed This Past Week

Quest Diagnostics (NYSE: DGX) shares rose over 8% last week after the company raised its full-year outlook. In Q2, revenue increased 10% to $3 billion, with adjusted EPS up 19% to $3.12. Quest projects full-year revenue around $12 billion and adjusted EPS of $11.05 to $11.25, citing growth and margin gains from automation and AI.

yahoo.com4 min
JUL 23
$DGXMedAI 9/10

Quest Diagnostics Boosts FY26 Outlook; Shares Up 5.7% - Update

Quest Diagnostics (DGX) reported Q2 results and raised its FY2026 guidance. It now expects GAAP earnings of $9.97 to $10.17 per share and adjusted earnings of $11.05 to $11.25, on revenue of $11.95B to $12.05B, versus prior ranges of $9.58 to $9.78, $10.63 to $10.83, and $11.78B to $11.90B. Shares were up 5.71% premarket.

rttnews.com2 min